Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OBI-833
- Development stage
- Phase 2
- Lead developer
- OBI Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
OBI-833 is a carbohydrate-based therapeutic cancer vaccine designed as an active immunotherapy. It consists of the tumor-associated carbohydrate antigen Globo H conjugated to CRM197 (a non-toxic mutant of diphtheria toxin) and is administered with the adjuvant OBI-821 to enhance immune response. The mechanism involves stimulating the immune system to generate anti-Globo H antibodies (IgM and IgG), leading to complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing Globo H. Developed by Academia Sinica and further advanced by OBI Pharma, it targets epithelial cancers that express the Globo H antigen, including non-small cell lung cancer (NSCLC) and biliary tract cancers such as cholangiocarcinoma[2][4][5][6][8][9].
- Brand names
- OBI-833OBI833OBI 833
- Other names
- Globo H-DT vaccineGlobo H-CRM197 vaccine
02
Targets
Globo-H
Beyond the preview
Go deeper on OBI-833.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBI-833.